Home › Funds › GILEAD SCIENCES, INC. › RCUS

GILEAD SCIENCES, INC. position in RCUS

ARCUS BIOSCIENCES INC · Health Care

GILEAD SCIENCES, INC. reported holding 31,424,760 shares of RCUS (ARCUS BIOSCIENCES INC) in its Q3 2026 13F filing — a position valued at US$811.7M, representing 55.45% of its reported portfolio and ranking #1 among its reported holdings. GILEAD SCIENCES, INC. has disclosed RCUS holdings in 8 of the last 8 reported quarters, going back to Q4 2024.

Latest position (Q3 2026)31.42M sh
Reported value held$811.70M
Portfolio Weight55.45%
First reportedQ4 2024
Last changeHold
Updated2026-11-06

Last updated: 2026-11-06 · Source: SEC EDGAR Form 13F-HR

How GILEAD SCIENCES, INC.'s RCUS position evolved

GILEAD SCIENCES, INC. first disclosed a stake in RCUS in Q4 2024 at 30,061,124 shares (US$447.6M). The position peaked in Q2 2026 at 31,424,760 shares, worth US$968.8M. Across 8 filings, GILEAD SCIENCES, INC. increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 6 time(s). The most recent filing (Q3 2026) shows 31,424,760 shares valued at US$811.7M.

Quarter by quarter

QuarterSharesValueChange
Q4 2024 30.06M $447.61M New
Q1 2025 31.42M $246.68M Add
Q2 2025 31.42M $255.80M Hold
Q3 2025 31.42M $427.38M Hold
Q4 2025 31.42M $748.85M Hold
Q1 2026 31.42M $678.77M Hold
Q2 2026 31.42M $968.83M Hold
Q3 2026 31.42M $811.70M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About RCUS and 13F data

RCUS (ARCUS BIOSCIENCES INC) is a Health Care company. 46 other funds we track also report a position in RCUS — the largest reported positions include MONTANOVA CAPITAL, LLC (US$147.3M), Siren, L.L.C. (US$74.6M), SAMLYN CAPITAL, LLC (US$47.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding RCUS

All RCUS fund holders →

FAQ

How long has GILEAD SCIENCES, INC. held RCUS?

GILEAD SCIENCES, INC. has disclosed RCUS holdings in 8 of the last 8 reported quarters, going back to Q4 2024.

What is GILEAD SCIENCES, INC.'s current position in RCUS?

As of Q3 2026, GILEAD SCIENCES, INC. holds 31.42M shares of RCUS (ARCUS BIOSCIENCES INC), valued at $811.70M, representing 55.45% of its reported portfolio and ranking #1.

Has GILEAD SCIENCES, INC. been buying or selling RCUS?

In the latest 13F filing (Q3 2026), GILEAD SCIENCES, INC. held unchanged its position in RCUS. The position peaked in Q2 2026 at 31.42M shares.

Which other funds hold RCUS?

Other major institutional holders of RCUS include MONTANOVA CAPITAL, LLC, Siren, L.L.C., SAMLYN CAPITAL, LLC, among 46 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.